New Jersey Health Reporter
SEE OTHER BRANDS

Get your health and wellness news from New Jersey

New Jersey Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.

Press releases published on July 24, 2025

The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results

The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results

SCOTTSDALE, Ariz., July 24, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its second quarter 2025 financial results on Thursday …

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at …

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 …

Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck

Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck

BRECKENRIDGE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly celebrates International Tequila Day with the launch of Casa …

Microbix Exhibiting & Presenting at ADLM

Microbix Exhibiting & Presenting at ADLM

MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association …

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the …

TCG Labs Soleil Raises an Additional $400 Million and Expands Global R&D Capabilities

TCG Labs Soleil Raises an Additional $400 Million and Expands Global R&D Capabilities

SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R…

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Appoints Julianne Averill to its Board of Directors

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board …

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation …

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has …

Javvy Protein Coffee Officially Launches, Redefining Javy Coffee Protein United States & Canada

Javvy Protein Coffee Officially Launches, Redefining Javy Coffee Protein United States & Canada

New York City, NY, July 24, 2025 (GLOBE NEWSWIRE) -- A new era of functional wellness beverages begins with the highly anticipated launch of Javvy Protein Coffee, a groundbreaking product that redefines the traditional coffee experience. Developed with a …

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides an …

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on …

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex …

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2

Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion) Regulatory submissions underway for zongertinib and nerandomilast, with launches expected in H2 2025 Strategic investments in …

Citryll Announces Formation of Scientific Advisory Board

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Board comprises world-renowned experts in biology, immunology and pathology Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune- …

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION Paris, July …

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA

COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE AUTORISATION FAIT SUITE A LA VALIDATION DU PROTOCOLE PAR L’EMA …

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused …

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

July 24, 2025 Amsterdam, the Netherlands – argenx (Euronext …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions